U.S. Food and Drug Administration Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 ≥1%
PRINCETON, N.J.--(BUSINESS WIRE) May 15, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2020 Category: Drugs & Pharmacology Source Type: news
Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer.
Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients.
Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb.
The study is being conducted at...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news
CheckMate-743 Trial of Nivolumab, Ipilimumab Meets Primary Endpoint in Mesothelioma Trial
The trial evaluating nivolumab in combination with ipilimumab in previously untreated malignant pleural mesothelioma met its primary endpoint of overall survival. (Source: CancerNetwork)
Source: CancerNetwork - April 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA Grants Priority Review to Nivolumab Plus Ipilimumab to Treat NSCLC
Bristol Myers Squibb recently announced that the FDA granted priority review to nivolumab plus ipilimumab in combination with chemotherapy as a first-line treatment for metastatic NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - April 8, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Patients of Metastatic Prostate Cancer Could Benefit from Immunotherapy Treatment
A recent study found that a group of patients with metastatic castration-resistant prostate cancer responded positively to treatment with ipilimumab, prolonging survival after treatment in the “favorable” cohort. (Source: CancerNetwork)
Source: CancerNetwork - April 7, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
FDA Approves Immunotherapy Combo for Liver Cancer FDA Approves Immunotherapy Combo for Liver Cancer
Nivolumab and ipilimumab together produce a response rate double that of nivolumab alone in advanced hepatocellular carcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
U.S. Food and Drug Administration approves Opdivo ® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
Bristol Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib.1,2 Approval for this indication has been granted under accelerated approval based on (Source: World Pharma News)
Source: World Pharma News - March 11, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
FDA Approves Nivolumab-Ipilimumab Combo for Hepatocellular Carcinoma
The FDA approved the combination use of nivolumab plus ipilimumab for the treatment of patients with HCC who have been previously treated with sorafenib. (Source: CancerNetwork)
Source: CancerNetwork - March 11, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Some Rare Neuroendocrine Tumors May Respond to Ipilimumab Plus Nivolumab Some Rare Neuroendocrine Tumors May Respond to Ipilimumab Plus Nivolumab
Patients with fast-growing non-pancreatic neuroendocrine tumors may respond to combination therapy with ipilimumab plus nivolumab, according to findings within the Dual Anti-CTLA-4& Anti-PD-1 blockade in Rare Tumors (DART) trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 5, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Pre-operative immunotherapy triggers encouraging response in oral cancers
(American Society for Radiation Oncology) A new clinical trial suggests that immunotherapy given before other treatments for oral cavity cancers can elicit an immune response that shrinks tumors, which could provide long-term benefit for patients. In the randomized trial, two neoadjuvant doses of nivolumab given with or without ipilimumab led to complete or partial tumor shrinkage in most cases and did not delay any patients from continuing on to standard treatment. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news
Mesothelioma Clinical Trial Involves Immunotherapy Before Surgery
Three of the country’s leading cancer centers have opened a collaborative clinical trial that potentially could change surgical treatment of mesothelioma.
Researchers will measure the safety and efficacy of using two different immunotherapy drug regimens — Opdivo (nivolumab) and Yervoy (ipilimumab) — beginning 42 days before surgery.
The hope is that at least one will make surgical resection more effective.
Sidney Kimmel Cancer Center at Johns Hopkins University, MD Anderson Cancer Center at the University of Texas and Greenebaum Cancer Center at the University of Maryland are working together to enroll at least 30 p...
Source: Asbestos and Mesothelioma News - February 24, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news
U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
Bristol-Myers Squibb Company (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. (Source: World Pharma News)
Source: World Pharma News - January 17, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLC
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 15, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Immunotherapy is safe following chemoradiotherapy for women with node-positive cervical cancer
(NRG Oncology) Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 27, 2019 Category: Cancer & Oncology Source Type: news
